EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi

Mario Ballerini, Elisa Lucchini, Emanuele Ravano, Jessica Rosa, Caterina Patti, Annalisa Arcari, Federica Cavallo, Laura Ballotta, Giacomo Loseto, Andrea Evangelista, Valentina Tabanelli, Francesco Zaja

Annals of Hematology · 28.05.2026 · 105 (8)

DOI: 10.1007/s00277-026-06852-1 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, online erschienen am 28.05.2026. Verfasst von Mario Ballerini und 11 weiteren Autor:innen. Beteiligte Einrichtung: UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, T-Cell, Peripheral, Antibodies, Monoclonal, ADP-ribosyl Cyclase 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, T-Cell, PeripheralAntibodies, MonoclonalADP-ribosyl Cyclase 1Membrane GlycoproteinsHumansDeoxycytidineFemaleCisplatinDexamethasoneGemcitabineMaleAgedMiddle AgedAdultItalyNeutropenia

Stichwörter der Autor:innen

CD38DaratumumabGDPPTCLRelapsed/refractoryT-cell lymphoma

Substanzen

Antibodies, MonoclonaldaratumumabADP-ribosyl Cyclase 1DeoxycytidineCisplatinDexamethasoneGemcitabineMembrane GlycoproteinsCD38 protein, human

Autor:innen und Institutionen

  • UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
  • UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy. elisa.lucchini@asugi.sanita.fvg.it.
  • SC Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Ematologia, Meldola, Italy.
  • UOC Oncoematologia Azienda Villa Sofia Cervello, Palermo, Italy.
  • UO Ematologia, Ospedale Guglielmo da Saliceto, Piacenza, Italy.

Zitieren

APA

Ballerini, M., Lucchini, E., Ravano, E., Rosa, J., Patti, C., Arcari, A., Cavallo, F., Ballotta, L., Loseto, G., Evangelista, A., Tabanelli, V., & Zaja, F. (2026). Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Annals of Hematology, 105(8). https://doi.org/10.1007/s00277-026-06852-1

Vancouver

Ballerini M, Lucchini E, Ravano E, Rosa J, Patti C, Arcari A, et al. Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Annals of Hematology. 2026;105(8). doi:10.1007/s00277-026-06852-1

BibTeX
@article{Ballerini2026,
  author = {Ballerini, Mario and Lucchini, Elisa and Ravano, Emanuele and Rosa, Jessica and Patti, Caterina and Arcari, Annalisa and Cavallo, Federica and Ballotta, Laura and Loseto, Giacomo and Evangelista, Andrea and Tabanelli, Valentina and Zaja, Francesco},
  title = {Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {8},
  doi = {10.1007/s00277-026-06852-1}
}
Kostenlos starten →